These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 37758275)

  • 1. Sarcoidosis-associated pulmonary fibrosis: joining the dots.
    Bandyopadhyay D; Mirsaeidi MS
    Eur Respir Rev; 2023 Sep; 32(169):. PubMed ID: 37758275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel insights in fibrotic pulmonary sarcoidosis.
    Comes A; Sofia C; Richeldi L
    Curr Opin Pulm Med; 2022 Sep; 28(5):478-484. PubMed ID: 35838359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
    BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN
    Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An expert overview of pulmonary fibrosis in sarcoidosis.
    Gupta R; Kim JS; Baughman RP
    Expert Rev Respir Med; 2023 Feb; 17(2):119-130. PubMed ID: 36861987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence.
    Richeldi L; Varone F; Bergna M; de Andrade J; Falk J; Hallowell R; Jouneau S; Kondoh Y; Morrow L; Randerath W; Strek M; Tabaj G
    Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances with pharmacotherapy for the treatment of interstitial lung disease.
    Comes A; Sgalla G; Perrotta A; Richeldi L
    Expert Opin Pharmacother; 2022 Mar; 23(4):483-495. PubMed ID: 34907821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrosing interstitial lung diseases: knowns and unknowns.
    Cottin V; Wollin L; Fischer A; Quaresma M; Stowasser S; Harari S
    Eur Respir Rev; 2019 Mar; 28(151):. PubMed ID: 30814139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes.
    Patterson KC; Strek ME
    Ann Am Thorac Soc; 2013 Aug; 10(4):362-70. PubMed ID: 23952859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From granuloma to fibrosis: sarcoidosis associated pulmonary fibrosis.
    Bonham CA; Strek ME; Patterson KC
    Curr Opin Pulm Med; 2016 Sep; 22(5):484-91. PubMed ID: 27379967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Computed tomography in evaluating the development of different types of pulmonary fibrosis in patients with interstitial lung diseases].
    Speranskaya AA; Novikova LN; Baranova OP; Dvorakovskaya IV; Kameneva MY; Amosova NA
    Vestn Rentgenol Radiol; 2015; (4):5-11. PubMed ID: 26552223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease.
    Sarkar P; Avram C; Chaudhuri N
    Expert Rev Respir Med; 2020 Oct; 14(10):1001-1008. PubMed ID: 32567402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary sarcoidosis complicated by rheumatoid arthritis in a patient presenting with progressive fibrosing interstitial lung disease and treated with nintedanib: a case report and literature review.
    Suzuki A; Kamio K; Takeno M; Terasaki Y; Taniuchi N; Sato J; Nishijima N; Saito Y; Seike M; Gemma A; Azuma A
    Ther Adv Respir Dis; 2023; 17():17534666231158279. PubMed ID: 36872912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
    Makino S
    Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrotic Pulmonary Sarcoidosis.
    Nunes H; Brillet PY; Bernaudin JF; Gille T; Valeyre D; Jeny F
    Clin Chest Med; 2024 Mar; 45(1):199-212. PubMed ID: 38245367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapidly non-ipf progressive fibrosing interstitial lung disease: a phenotype with an ipf-like behavior.
    Khine N; Mudawi D; Rivera-Ortega P; Leonard C; Chaudhuri N; Margaritopoulos GA
    Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):231-233. PubMed ID: 33093788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct Airway Involvement in Subtypes of End-Stage Fibrotic Pulmonary Sarcoidosis.
    Verleden SE; Vanstapel A; De Sadeleer L; Dubbeldam A; Goos T; Gyselinck I; Geudens V; Kaes J; Van Raemdonck DE; Ceulemans LJ; Yserbyt J; Vos R; Vanaudenaerde B; Weynand B; Verschakelen J; Wuyts WA
    Chest; 2021 Aug; 160(2):562-571. PubMed ID: 33440183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
    Gibson CD; Kugler MC; Deshwal H; Munger JS; Condos R
    Lung; 2020 Aug; 198(4):597-608. PubMed ID: 32591895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical and immunologic features of pulmonary fibrosis in sarcoidosis.
    Patterson KC; Hogarth K; Husain AN; Sperling AI; Niewold TB
    Transl Res; 2012 Nov; 160(5):321-31. PubMed ID: 22683422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies.
    Wongkarnjana A; Scallan C; Kolb MRJ
    Curr Opin Pulm Med; 2020 Sep; 26(5):436-442. PubMed ID: 32657838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.